Compare Figs Inc (FIGS) vs 10X Genomics Inc (TXG) Price & Performance

FIGS stock trades at $14.50, up 0.76% today, with strong technical momentum and bullish moving averages. Recent Q2 2026 earnings beat expectations with $0.11 EPS and 29% revenue growth, leading to a raised 2026 outlook. The company maintains a high gross margin of 68.91% but faces valuation concerns with a P/E of 43.24. Analyst sentiment is positive with a $19.50 consensus price target.

Outlook remains favorable due to accelerating revenue growth and margin expansion, though the rich valuation and execution risks in H2 2026 pose challenges. Institutional buying and a $100 million share buyback program support bullish sentiment, but investors should weigh premium multiples against growth sustainability.

TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.

Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.